DK2125786T3 - Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin - Google Patents

Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin

Info

Publication number
DK2125786T3
DK2125786T3 DK07858987.6T DK07858987T DK2125786T3 DK 2125786 T3 DK2125786 T3 DK 2125786T3 DK 07858987 T DK07858987 T DK 07858987T DK 2125786 T3 DK2125786 T3 DK 2125786T3
Authority
DK
Denmark
Prior art keywords
methyl
pyrazol
pyridin
quinoline
phenoxy
Prior art date
Application number
DK07858987.6T
Other languages
Danish (da)
English (en)
Inventor
Patrick Robert Vorhoest
Caroline Proulx
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39321475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2125786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK2125786T3 publication Critical patent/DK2125786T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK07858987.6T 2006-12-21 2007-12-03 Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin DK2125786T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87126006P 2006-12-21 2006-12-21
PCT/IB2007/003819 WO2008084299A1 (en) 2006-12-21 2007-12-03 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Publications (1)

Publication Number Publication Date
DK2125786T3 true DK2125786T3 (da) 2011-05-09

Family

ID=39321475

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07858987.6T DK2125786T3 (da) 2006-12-21 2007-12-03 Succinatsalt af 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl) quinolin

Country Status (24)

Country Link
US (1) US8283471B2 (enExample)
EP (1) EP2125786B1 (enExample)
JP (1) JP5254602B2 (enExample)
KR (2) KR20090092338A (enExample)
CN (1) CN101611029B (enExample)
AR (1) AR064417A1 (enExample)
AT (1) ATE502028T1 (enExample)
AU (1) AU2007343135B2 (enExample)
BR (1) BRPI0720936A2 (enExample)
CA (1) CA2673435C (enExample)
CY (1) CY1111919T1 (enExample)
DE (1) DE602007013294D1 (enExample)
DK (1) DK2125786T3 (enExample)
ES (1) ES2360014T3 (enExample)
IL (1) IL199389A (enExample)
MX (1) MX2009006528A (enExample)
NZ (1) NZ577716A (enExample)
PL (1) PL2125786T3 (enExample)
PT (1) PT2125786E (enExample)
RU (1) RU2430918C2 (enExample)
SI (1) SI2125786T1 (enExample)
TW (1) TWI359660B (enExample)
WO (1) WO2008084299A1 (enExample)
ZA (1) ZA200904230B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US20120214842A1 (en) * 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
KR102233916B1 (ko) * 2019-05-28 2021-03-30 주식회사 엘지생활건강 Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EA011451B1 (ru) * 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006072828A2 (en) * 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2006078825A2 (en) 2005-01-21 2006-07-27 Cabot Corporation Processes for forming nanoparticles
AU2006329849A1 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound

Also Published As

Publication number Publication date
CA2673435C (en) 2012-10-09
KR20090092338A (ko) 2009-08-31
BRPI0720936A2 (pt) 2014-03-11
AR064417A1 (es) 2009-04-01
ATE502028T1 (de) 2011-04-15
JP5254602B2 (ja) 2013-08-07
AU2007343135A1 (en) 2008-07-17
IL199389A (en) 2014-01-30
CN101611029A (zh) 2009-12-23
HK1134670A1 (en) 2010-05-07
EP2125786B1 (en) 2011-03-16
PL2125786T3 (pl) 2011-07-29
EP2125786A1 (en) 2009-12-02
SI2125786T1 (sl) 2011-05-31
TWI359660B (en) 2012-03-11
MX2009006528A (es) 2009-06-26
WO2008084299A1 (en) 2008-07-17
NZ577716A (en) 2012-10-26
PT2125786E (pt) 2011-04-21
US20100063089A1 (en) 2010-03-11
CY1111919T1 (el) 2015-11-04
ES2360014T3 (es) 2011-05-31
RU2009123347A (ru) 2011-01-27
ZA200904230B (en) 2010-04-28
TW200833337A (en) 2008-08-16
AU2007343135B2 (en) 2013-03-21
JP2008208114A (ja) 2008-09-11
RU2430918C2 (ru) 2011-10-10
CA2673435A1 (en) 2008-07-17
DE602007013294D1 (de) 2011-04-28
KR20120043775A (ko) 2012-05-04
CN101611029B (zh) 2014-09-10
US8283471B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
IL269977B (en) 2-(1-isopropyl-pyrazol-5-yl)-3-(hydroxy/chloro)methyl-pyridine compounds
ATE516272T1 (de) 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
DK3170818T3 (da) Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
DK2049487T3 (da) Fremgangsmåde til fremstilling af 2-substituerede 5-(1-alkylthio)alkylpyridiner
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
ATE502013T1 (de) Pyridonderivate als inhibitoren von p38a-mapk
BRPI0912855A2 (pt) derivados de indazóis substituídos por fenila ou piridinila
SI2625175T1 (sl) Kristaliničen (r)-(e)-2-(4-(2-(5-(1-(3,5-dikloropiridin-4-il)etoksi)- 1h-indazol-3-il)vinil-1h-pirazol-1-il)etanol in njegova uporaba kot inhibitor fgfr
ATE475649T1 (de) Pyridincarboxamide als 11-beta-hsd1-inhibitoren
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
IL206470A (en) 2-Amino-1 - ((Phosphonooxy) Methyl) -3 - (3 - ((4 - ((2-Pyridinyloxy) Methyl) Phenyl) Methyl) -5-Isoxazolyl) - Pyridinium and Pharmaceutical Preparation Containing It
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
DE602005008079D1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE AS MPGES-1 INHIBITORS
DK1720531T3 (da) Nye sammensætninger indeholdende quinolinforbindelser
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602005006744D1 (de) Chinolinderivate zur verwendung als inhibitoren von mycobakterien
DK2155717T3 (da) 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister
ATE472543T1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
ATE502028T1 (de) Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)- 1h-pyrazol-3-yl)phenoxy)methyl)chinolin
IL220851A (en) Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process
DK2296473T3 (da) Virksomt 4-(3-alkylsulfinylbenzoyl) pyrazol-herbicid